Robert C James1, Cameron A Mustard. 1. Department of Community Health Sciences, University of Manitoba Faculty of Medicine, Winnipeg, Canada.
Abstract
OBJECTIVE: We examined the location of commercial plasma donation centers in the United States over the period 1980 to 1995 relative to the geographic distribution of risk behaviors associated with transfusion-transmissible infections. METHODS: The census tract locations of commercial source plasma clinics were described by measures of neighborhood social disadvantage and the prevalence of illicit drug use and active local drug economies. RESULTS: Depending on the measure of social environment used, commercial plasma clinics were 5 to 8 times more likely to be located in census tracts designated high-risk than would be expected by chance. CONCLUSIONS: Commercial source plasma clinics were overrepresented in neighborhoods with very active local drug economies. These patterns persisted after the links between human immunodeficiency virus and hepatitis C virus infections and plasma products had been established and may present risks to blood system safety.
OBJECTIVE: We examined the location of commercial plasma donation centers in the United States over the period 1980 to 1995 relative to the geographic distribution of risk behaviors associated with transfusion-transmissible infections. METHODS: The census tract locations of commercial source plasma clinics were described by measures of neighborhood social disadvantage and the prevalence of illicit drug use and active local drug economies. RESULTS: Depending on the measure of social environment used, commercial plasma clinics were 5 to 8 times more likely to be located in census tracts designated high-risk than would be expected by chance. CONCLUSIONS: Commercial source plasma clinics were overrepresented in neighborhoods with very active local drug economies. These patterns persisted after the links between human immunodeficiency virus and hepatitis C virus infections and plasma products had been established and may present risks to blood system safety.
Authors: L Saxe; C Kadushin; A Beveridge; D Livert; E Tighe; D Rindskopf; J Ford; A Brodsky Journal: Am J Public Health Date: 2001-12 Impact factor: 9.308
Authors: D D Chitwood; J B Page; M Comerford; J A Inciardi; C B McCoy; E Trapido; S H Lai Journal: Am J Public Health Date: 1991-05 Impact factor: 9.308
Authors: Peter D Weinberg; Jennie Hounshell; Laurence A Sherman; John Godwin; Shirin Ali; Cecilia Tomori; Charles L Bennett Journal: Ann Intern Med Date: 2002-02-19 Impact factor: 25.391
Authors: Lynne C Messer; Barbara A Laraia; Jay S Kaufman; Janet Eyster; Claudia Holzman; Jennifer Culhane; Irma Elo; Jessica G Burke; Patricia O'Campo Journal: J Urban Health Date: 2006-11 Impact factor: 3.671
Authors: Patricia Volkow; Kimberly C Brouwer; Oralia Loza; Rebeca Ramos; Remedios Lozada; Richard S Garfein; Carlos Magis-Rodriguez; Michelle Firestone-Cruz; Steffanie A Strathdee Journal: Int J Drug Policy Date: 2009-02-20
Authors: Andrew Rundle; Kathryn M Neckerman; Daniel Sheehan; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki Journal: Cancer Causes Control Date: 2012-12-08 Impact factor: 2.506